

Riber

MBE system sales supported FY19 recovery

A doubling in revenues from MBE systems during FY19 compensated for a reduction in evaporator sales and supported an improvement in reported EBIT from €0.0m to €0.9m. Order cover for FY20 is good and management does not anticipate that the COVID-19 pandemic will affect deliveries for FY20 overall, although performance will be second-half weighted. We will leave our FY20 estimates unchanged until the detailed FY19 accounts are released at the end of April.

Year end	Revenue (€m)	EBIT (€m)	PAT (€m)	DPS (€)	P/E (x)	Yield (%)
12/17	30.5	3.8	4.1	0.05	7.3	3.6
12/18	31.3	0.0	0.3	0.05	99.2	3.6
12/19	33.4	0.9	1.1	0.03	27.0	2.1
12/20e	37.7	3.0	3.0	0.05	9.9	3.6

Source: Company data, Edison Investment Research estimates

As announced in January, total revenues grew by 7% year-on-year to \in 33.4m, with a more than doubling in revenues from molecular beam epitaxy (MBE) systems offsetting substantially lower evaporator sales. Total sales were below our \in 35.3m estimate because billing issues affected sales of services and accessories during Q4. Gross margin dropped from 35.6% to 29.6%, reflecting a lower proportion of evaporators. Indirect costs fell by \in 2m, primarily because FY18 exceptional items included the \in 1.1m cost of the allocation of shares for a staff bonus scheme. Reported EBIT recovered sharply (from \in 0.0m to \in 0.9m), while not reaching our \in 1.5m estimate because of production inefficiencies, which have been resolved. Cash generation was strong, with net cash increasing by \in 3.4m during FY19 to \in 5.9m at the year end.

The €28.7m FY19 year-end order book was comprised of €21.8m for MBE systems, representing 12 machines for delivery in FY20, five of which are larger production systems, and €6.9m for services and accessories. Riber's manufacturing facility has remained operational through the COVID-19 pandemic, although supplier issues may cause some deliveries to slip into H220. Travel restrictions are causing delays in signing contracts, particularly with customers in China. Management does not expect this to have an impact on deliveries for FY20 overall, but to accentuate the second-half performance weighting. Since Riber's MBE systems are used in research on new materials and for the production of electronic and optoelectronic devices used in communications networks, demand remains buoyant at present but may be impaired longer term if investment is affected by a global recession.


FY19 preliminary results

Tech hardware & equipment

27 /	27 April 2020	
Price	€1.40	
Market cap	€30m	
Net cash (€m) at end December 2019	5.9	
Shares in issue	21.3m	
Free float	51.3%	
Code	RIB	
Primary exchange E	uronext Paris	

Secondary exchange	N/A
j-	

Share price performance



Business description

Riber designs and produces molecular beam epitaxy (MBE) systems and evaporator sources and cells for the semiconductor industry. This equipment is essential for the manufacturing of compound semiconductor materials that are used in numerous high-growth applications.

Analysts

Anne Margaret Crow	+44 (0)20 3077 5700
Dan Ridsdale	+44 (0)20 3077 5729
tech@edisongroup.com	

Edison profile page

Riber is a research client of Edison Investment Research Limited



General disclaimer and copyright

This report has been commissioned by Riber and prepared and issued by Edison, in consideration of a fee payable by Riber. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2020 Edison Investment Research Limited (Edison)

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPD and (iii) persons to whom it is otherwise lawful to distributed it. The investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tallored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom New York +1 646 653 7026 1,185 Avenue of the Americas 3rd Floor, New York, NY 10036 United States of America Sydney +61 (0)2 8249 8342 Level 4, Office 1205 95 Pitt Street, Sydney NSW 2000, Australia